The increase in revenue was due to $44.2m of profit share earned from commercial sales of Enoxaparin sodium injection and the $5m regulatory milestone earned upon FDA marketing approval of eEnoxaparin sodium injection in July of 2010.
Momenta has posted a net income of $32.12m for the third quarter 2010, or $0.70 per diluted share, compared to net loss of $14.65m, or $0.38 loss per diluted share, for the comparable period in 2009.
Momenta’s operating income was $32.15m, compared to operating loss of $14.54m for the comparable period in 2009.
For the nine months ended 30 September 2010, revenue was $58.45m, compared to $14.6m for the year ago period.
Operating income was $1.17m for the nine months ended 30 September 2010, compared to $49.52m for the year ago period.
Net loss was $1.03m, or $0.02 per diluted share, compared to $49.32m, or $1.27 loss per diluted share, for the year ago period.